, L'innocuité de la valériane pendant la grossesse et l'allaitement n'a pas été établie. En l'absence de données suffisantes, l'utilisation de la plante pendant la grossesse et l'allaitement n'est pas recommandée

, Contre-indications

, La valériane est contre-indiquée en cas d'hypersensibilité à la plante

, De plus, lorsqu'elle est utilisée comme « additif de bain », la valériane est contre-indiqué en cas de plaies ouvertes, de lésions importantes de la peau, de fortes fièvre, d'infections graves

, Spécialités médicamenteuses disponibles en pharmacie

, A) Valériane seule -ARKOGELULES ® VALERIANE (gélule) : poudre de rhizome de valériane ? 350 mg/gélule

. -elusanes-®, VALERIANE 200 mg (gélule) : extrait sec de racine de valériane ? 200 mg/gélule

, Valériane en association -BIOCARDE ® (solution buvable) : teinture de valériane ? 15 ml/100 ml. En association avec aubépine, passiflore, avoine, mélisse

. -dormicalm-®, comprimé enrobé) : extrait sec de racine de valériane ? 125 mg/comprimé. En association avec mélisse et passiflore

. -euphytose-®, comprimé enrobé) : extrait sec de valériane ? 50 mg/comprimé. En association avec passiflore, aubépine

. -spasmine-®, enrobé) : extrait sec de racine de valériane ? 120

, En association avec aubépine

. -tranquital-®, comprimé enrobé) : extrait sec aqueux de racine de valériane ? 34,6 mg/comprimé. En association avec aubépine

M. Valeriana, Le pharmacien analyse la situation et décèle rapidement une interaction pouvant expliquer la fatigue anormale du patient. La prométhazine est un antihistaminique de la famille des phénothiazines qui possède entre autre des propriétés sédatives, et la valériane est une plante utilisée pour traiter l'anxiété et les troubles du sommeil. L'association de ces deux spécialités avec l'alcool, qui est également sédatif, vol.44

/. Le-pharmacien, association de son traitement antihistaminique, de la spécialité à base de valériane et d'une consommation importante d'alcool a provoqué une forte sédation qui est à l'origine de son état actuel. Il lui conseille donc d'arrêter le traitement par valériane et d'éviter de consommer de l'alcool, ou du moins de le consommer avec modération, étant donné que cela peut augmenter l'effet sédatif de son traitement antihistaminique. Enfin, pour diminuer son stress

, Le pharmacien d'officine joue donc un rôle crucial dans la dispensation des spécialités à base de plantes. C'est à lui de conseiller les patients et d'être attentif aux notions de bon usage et de toxicité liées à ces produits souvent considérés comme inoffensifs par ses utilisateurs. Il peut poser les bonnes questions à ses patients pour assurer la sécurité de leur emploi et peut repérer les interactions médicamenteuses, La phytothérapie, seule ou en association avec d'autres produits, fait intervenir des composants naturels actifs qui ne sont pas sans risques

, La dispensation des spécialités liées à la phytothérapie exige le même niveau de vigilance que celle de médicaments allopathiques. C'est donc en s'appuyant entre autre sur sa formation en botanique, en pharmacognosie et en biologie végétale, que le pharmacien doit s'assurer de l'absence d'interactions médicamenteuses ou de contre-indications. En d'autres termes, il doit aujourd'hui

. Enfin and . Qu, en cas de doute sur l'innocuité d'une plante vis-à-vis d'un traitement ou d'une pathologie, le pharmacien d'officine peut se tourner vers l'un des centres régionaux de pharmacovigilance

, Ce travail n'est pas exhaustif et peut donc s'étendre aux autres plantes mais également à l'aromathérapie qui est elle aussi de plus en plus sollicitée par les patients à la recherche d'alternative thérapeutique naturelle

, Ensemble, patients, pharmaciens, et autres professionnels de santé, soyons phytovigilants. REFERENCES BIBLIOGRAPHIQUES

, Observatoire sociétal du médicament 2011 -TNS-Sofres pour Les entreprises du médicament, LEEM, 2011.

, ANSM : Agence nationale de sécurité du médicament et des produits de santé. Pharmacopée française -11e édition, p.29, 2019.

, Direction européenne de la qualité du médicament & soins de santé (EDQM). Pharmacopée Européenne -10e édition, 2020.

. Qu'est-ce-que-la-pharmacopée, ANSM : Agence nationale de sécurité du médicament et des produits de santé

H. Lehmann and J. Pabst, La phytovigilance : impératif médical et obligation légale, Ann Pharm Fr. janv, vol.74, issue.1, pp.49-60, 2016.

, Organisation de la pharmacovigilance nationale -ANSM : Agence nationale de sécurité du médicament et des produits de santé

L. , évaluation, d'expertise et de décision -ANSM : Agence nationale de sécurité du médicament et des produits de santé

, Centres régionaux de pharmacovigilance -ANSM : Agence nationale de sécurité du médicament et des produits de santé

, Rôle des différents acteurs -ANSM : Agence nationale de sécurité du médicament et des produits de santé

. Pharmacodépendance, ANSM : Agence nationale de sécurité du médicament et des produits de santé

, Addictovigilance -ANSM : Agence nationale de sécurité du médicament et des produits de santé

, Le dispositif national de Toxicovigilance | Anses -Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail

D. Sur,

J. Bruneton, Pharmacognosie -Phytochimie, Plantes médicinales -5e édition, 2016.

K. Ried, C. Toben, and P. Fakler, Effect of garlic on serum lipids: an updated meta-analysis, Nutr Rev. mai, vol.71, issue.5, pp.282-99, 2013.

, European Medicines Agency. European Union herbal monograph on Allium sativum L. bulbus. 12 juill, p.7, 2016.

M. Blumenthal and . Dir, The Complete German Commission E Monographs, 1998.

S. M. Carden, W. V. Good, P. A. Carden, and R. M. Good, Garlic and the strabismus surgeon, Clin Experiment Ophthalmol. août, vol.30, issue.4, pp.303-307, 2002.

K. German, U. Kumar, and H. N. Blackford, Garlic and the risk of TURP bleeding, Br J Urol. oct, vol.76, issue.4, p.518, 1995.

S. Gravas, V. Tzortzis, C. Rountas, and M. D. Melekos, Extracorporeal shock-wave lithotripsy and garlic consumption: a lesson to learn, Urol Res. févr, vol.38, issue.1, pp.61-64, 2010.

K. D. Rose, P. D. Croissant, C. F. Parliament, and M. B. Levin, Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report, Neurosurgery. mai, vol.26, issue.5, pp.880-882, 1990.

. Ajoènes--wikiphyto,

D. Sur,

V. Vovolis, L. Kalogiros, D. Ivanova, and N. Koutsostathis, Garlic-induced severe anaphylaxis in a nonatopic patient, J Investig Allergol Clin Immunol, vol.20, issue.4, p.356, 2010.

W. Sunter, Warfarin and garlic. The pharmaceutical journal, vol.246, p.722, 1991.

A. Pathak, P. Leger, H. Bagheri, J. M. Senard, H. Boccalon et al., Garlic interaction with fluindione: a case report, Therapie, vol.58, issue.4, pp.380-381, 2003.

M. Mccoubrie, Doctors as patients: Lisinopril and garlic, Br J Gen Pract. févr, vol.46, issue.403, p.107, 1996.

S. C. Piscitelli, A. H. Burstein, N. Welden, K. D. Gallicano, and J. Falloon, The effect of garlic supplements on the pharmacokinetics of saquinavir, Clin Infect Dis, vol.34, issue.2, pp.234-242, 2002.

P. Dhamija, S. Malhotra, and P. Pandhi, Effect of oral administration of crude aqueous extract of garlic on pharmacokinetic parameters of isoniazid and rifampicin in rabbits, Pharmacology, vol.77, issue.2, pp.100-104, 2006.

J. A. Mennella and G. K. Beauchamp, Maternal diet alters the sensory qualities of human milk and the nursling's behavior, Pediatrics, vol.88, issue.4, pp.737-781, 1991.

. Ansm, Base de données publique des médicaments, 2019.

D. Sur,

. Vidal and . Vidal, Base de données médicamenteuse

. Vidal, , 2019.

D. Sur,

, European Medicines Agency. Crataegus spp

C. Daniele, G. Mazzanti, M. H. Pittler, and E. Ernst, Adverse-event profile of Crataegus spp.: a systematic review, Drug Saf, vol.29, issue.6, pp.523-558, 2006.

A. European-medicines, European Union herbal monograph on Crataegus spp., folium cum flore. 5 avr, vol.7, 2016.

A. Dasgupta, L. Kidd, B. J. Poindexter, and R. J. Bick, Interference of hawthorn on serum digoxin measurements by immunoassays and pharmacodynamic interaction with digoxin, Arch Pathol Lab Med. août, vol.134, issue.8, pp.1188-92, 2010.

R. Tankanow, H. R. Tamer, D. S. Streetman, S. G. Smith, J. L. Welton et al., Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha), J Clin Pharmacol. juin, vol.43, issue.6, pp.637-679, 2003.

E. Basch, C. Ulbricht, S. Basch, S. Dalton, E. Ernst et al., An evidence-based systemic review Echinacea E. angustifolia DC, E. pallida, E. purpurea by the Natural Standard Research Collaboration, J Herb Pharmacother, vol.5, issue.2, pp.57-88, 2005.

, European Medicines Agency. Echinacea pallida (Nutt.) Nutt., radix, 2018.

, Echinacea purpurea (L.) Moench, radix, European Medicines Agency, 2017.

A. European-medicines, Herbal medicine: summary for the public Purple coneflower herb, Echinacea Purpurea (L.) Moench., herba recens, vol.3, 2015.

A. European-medicines, European Union herbal monograph on Echinacea purpurea (L.) Moench, herba recens, vol.7, 2015.

J. Barnes, L. A. Anderson, S. Gibbons, and J. D. Phillipson, Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt.,Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties, J Pharm Pharmacol. août, vol.57, issue.8, pp.929-54, 2005.

R. J. Mullins and R. Heddle, Adverse reactions associated with echinacea: the Australian experience, Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. janv, vol.88, issue.1, pp.42-51, 2002.

S. L. Soon and R. I. Crawford, Recurrent erythema nodosum associated with Echinacea herbal therapy, J Am Acad Dermatol. févr, vol.44, issue.2, pp.298-307, 2001.

O. Kocaman, S. Hulagu, and O. Senturk, Echinacea-induced severe acute hepatitis with features of cholestatic autoimmune hepatitis, Eur J Intern Med. mars, vol.19, issue.2, p.148, 2008.

, Possible leukopenia associated with long-term use of echinacea

A. N. Lee and V. P. Werth, Activation of autoimmunity following use of immunostimulatory herbal supplements, Arch Dermatol. juin, vol.140, issue.6, pp.723-730, 2004.

J. L. Logan and J. Ahmed, Critical hypokalemic renal tubular acidosis due to Sjögren's syndrome: association with the purported immune stimulant echinacea, Clin Rheumatol. mai, vol.22, issue.2, pp.158-167, 2003.

A. European-medicines, European Union herbal monograph on Echinacea pallida, Nutt.) Nutt., radix. 5 juin, vol.7, 2018.

A. European-medicines, European Union herbal monograph on Echinacea purpurea (L.) Moench, radix, vol.7, 2017.

J. C. Gorski, S. Huang, A. Pinto, M. A. Hamman, J. K. Hilligoss et al., The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo, Clin Pharmacol Ther. janv, vol.75, issue.1, pp.89-100, 2004.

B. J. Gurley, S. F. Gardner, M. A. Hubbard, D. K. Williams, W. B. Gentry et al., In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto, Clin Pharmacol Ther, vol.76, issue.5, pp.428-468, 2004.

E. Ben-arye and N. Samuels, Patient-centered care in lung cancer: exploring the next milestones. Transl Lung Cancer Res, vol.4, pp.630-634, 2015.

, Pregnancy outcome following gestational exposure to echinacea: a prospective controlled study

D. Perri, J. Dugoua, E. Mills, and G. Koren, Safety and efficacy of echinacea (Echinacea angustafolia, E. purpurea and E. pallida) during pregnancy and lactation, Can J Clin Pharmacol J Can Pharmacol Clin, vol.13, issue.3, pp.262-267, 2006.

, Ginkgo biloba L., folium, European Medicines Agency, 2015.

A. European-medicines, European Union herbal monograph on Ginkgo biloba L., folium, vol.8, 2015.

, Hémorragies liées au Ginkgo biloba? Rev Prescrire, vol.27, pp.618-637, 2007.

A. S. Granger, Ginkgo biloba precipitating epileptic seizures, Age Ageing, vol.30, issue.6, pp.523-528, 2001.

L. Davydov and A. L. Stirling, Stevens-Johnson Syndrome with Ginkgo Biloba, J Herb Pharmacother. 1 janv, vol.1, issue.3, pp.65-74, 2001.

V. Russo, A. Rago, G. M. Russo, R. Calabrò, and G. Nigro, Ginkgo biloba: an ancient tree with new arrhythmic side effects, J Postgrad Med. sept, vol.57, issue.3, p.221, 2011.

C. Cianfrocca, F. Pelliccia, A. Auriti, and M. Santini, Ginkgo biloba-induced frequent ventricular arrhythmia, Ital Heart J Off J Ital Fed Cardiol, vol.3, issue.11, pp.689-91, 2002.

C. Meisel, A. Johne, and I. Roots, Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen, Atherosclerosis. avr, vol.167, issue.2, p.367, 2003.

T. Hoffman and . Ginko, Vioxx and excessive bleeding--possible drug-herb interactions: case report, Hawaii Med J. nov, vol.60, issue.11, p.290, 2001.

Y. S. Kim, M. K. Pyo, K. M. Park, P. H. Park, B. S. Hahn et al., Antiplatelet and antithrombotic effects of a combination of ticlopidine and ginkgo biloba ext (EGb 761), Thromb Res. 1 juill, vol.91, issue.1, pp.33-41, 1998.

A. J. Kellermann and C. Kloft, Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis, Pharmacotherapy. mai, vol.31, issue.5, pp.490-502, 2011.

J. Engelsen, J. D. Nielsen, and K. Hansen, Effect of Coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind

, Ugeskr Laeger. 28 avr, vol.165, issue.18, pp.1868-71, 2003.

X. Jiang, K. M. Williams, W. S. Liauw, A. J. Ammit, B. D. Roufogalis et al., Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects, Br J Clin Pharmacol. avr, vol.59, issue.4, pp.425-457, 2005.

T. Kupiec and V. Raj, Fatal seizures due to potential herb-drug interactions with Ginkgo biloba, J Anal Toxicol, vol.29, issue.7, pp.755-763, 2005.

C. Y. Yang, P. Chao, Y. C. Hou, S. Y. Tsai, K. C. Wen et al., Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats, Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc. sept, vol.44, issue.9, pp.1572-1580, 2006.

B. J. Gurley, S. F. Gardner, M. A. Hubbard, D. K. Williams, W. B. Gentry et al., Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans, Clin Pharmacol Ther. sept, vol.72, issue.3, pp.276-87, 2002.

V. F. Mauro, L. S. Mauro, J. F. Kleshinski, S. A. Khuder, Y. Wang et al., Impact of ginkgo biloba on the pharmacokinetics of digoxin, Am J Ther. août, vol.10, issue.4, pp.247-51, 2003.

, Interaction of Ginkgo biloba with efavirenz

D. Sur,

O. Yin, B. Tomlinson, M. Waye, A. Chow, and M. Chow, Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole, Pharmacogenetics. déc, vol.14, issue.12, pp.841-50, 2004.

M. Smith, K. M. Lin, and Y. P. Zheng, An open trial of nifedipine-herb interactions: nifedipine with St. John's wort, ginseng or Gingko biloba, Clin Pharmacol Ther, vol.69, p.86, 2001.

Y. Lin, S. Chu, and S. Tsai, Association between priapism and concurrent use of risperidone and Ginkgo biloba, Mayo Clin Proc, vol.82, issue.10, pp.1289-90, 2007.

R. M. Pinto, E. S. Fernandes, J. Reis, V. M. Peters, and O. Guerra-m-de, Intra-uterine growth retardation after prenatal administration of Ginkgo biloba to rats, Reprod Toxicol Elmsford N. juin, vol.23, issue.4, pp.480-485, 2007.

. Safety, Ginkgo biloba) during pregnancy and lactation

B. T. Gaffney, H. M. Hügel, and P. A. Rich, The effects of Eleutherococcus senticosus and Panax ginseng on steroidal hormone indices of stress and lymphocyte subset numbers in endurance athletes, Life Sci. 14 déc, vol.70, issue.4, pp.431-473, 2001.

, Efficacy and safety of the standardised Ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold -PubMed -NCBI

Y. Lee, Y. Jin, W. Lim, J. S. Choi, S. Jang et al., A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells, J Steroid Biochem Mol Biol. mars, vol.84, issue.4, pp.463-471, 2003.

, European Medicines Agency. Panax ginseng C.A. Meyer, 2017.

J. T. Coon and E. Ernst, Panax ginseng: a systematic review of adverse effects and drug interactions, Drug Saf, vol.25, issue.5, pp.323-367, 2002.

R. K. Siegel, Ginseng abuse syndrome. Problems with the panacea, JAMA. 13 avr, vol.241, issue.15, pp.1614-1619, 1979.

, Ginseng: a potential cause of long QT. -PubMed -NCBI

A. European-medicines, European Union herbal monograph on Panax ginseng C.A.Meyer, radix, 2014.

S. W. Ma, I. Benzie, T. Chu, B. Fok, B. Tomlinson et al., Effect of Panax ginseng supplementation on biomarkers of glucose tolerance, antioxidant status and oxidative stress in type 2 diabetic subjects: results of a placebo-controlled human intervention trial, Diabetes Obes Metab, vol.10, issue.11, pp.1125-1132, 2008.

V. Vuksan, M. Sung, J. L. Sievenpiper, P. M. Stavro, A. L. Jenkins et al., Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety, Nutr Metab Cardiovasc Dis NMCD. janv, vol.18, issue.1, pp.46-56, 2008.

N. Bilgi, K. Bell, A. N. Ananthakrishnan, and E. Atallah, Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity, Ann Pharmacother. mai, vol.44, issue.5, pp.926-934, 2010.

Y. Liu, J. Zhang, W. Li, H. Ma, J. Sun et al., Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes, Toxicol Sci Off J Soc Toxicol. juin, vol.91, issue.2, pp.356-64, 2006.

K. Janetzky and A. P. Morreale, Probable interaction between warfarin and ginseng, Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 15 mars, vol.54, issue.6, pp.692-695, 1997.

X. Jiang, K. M. Williams, W. S. Liauw, A. J. Ammit, B. D. Roufogalis et al., Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects, Br J Clin Pharmacol. mai, vol.57, issue.5, pp.592-601, 2004.

Y. H. Lee, B. K. Lee, Y. J. Choi, I. K. Yoon, B. C. Chang et al., Interaction between warfarin and Korean red ginseng in patients with cardiac valve replacement, Int J Cardiol, vol.145, issue.2, pp.275-281, 2010.

G. L. Henderson, M. R. Harkey, M. E. Gershwin, R. M. Hackman, J. S. Stern et al., Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity, Life Sci, vol.65, issue.15, pp.209-214, 1999.

D. Seely, J. Dugoua, P. D. Mills, E. Koren, and G. , Safety and efficacy of panax ginseng during pregnancy and lactation, Can J Clin Pharmacol J Can Pharmacol Clin, vol.15, issue.1, pp.87-94, 2008.

M. C. Lanhers, J. Fleurentin, F. Mortier, A. Vinche, and C. Younos, Anti-inflammatory and analgesic effects of an aqueous extract of Harpagophytum procumbens, Planta Med. avr, vol.58, issue.2, pp.117-140, 1992.

R. Soulimani, C. Younos, F. Mortier, and C. Derrieu, The role of stomachal digestion on the pharmacological activity of plant extracts, using as an example extracts of Harpagophytum procumbens, Can J Physiol Pharmacol. déc, vol.72, issue.12, pp.1532-1538, 1994.

A. European-medicines, Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix, 2016.

A. European-medicines, European Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix. 12 juill, vol.8, 2016.

J. Vlachojannis, B. D. Roufogalis, and S. Chrubasik, Systematic review on the safety of Harpagophytum preparations for osteoarthritic and low back pain, Phytother Res. févr, vol.22, issue.2, pp.149-52, 2008.

, Duodenal ulcer on devil's claw root tea, vol.43, p.1, 2012.

, Harpagophyton : ulcères et saignements digestifs ?, Prescrire Rédaction, vol.33, p.352, 2013.

D. Shaw, C. Leon, S. Kolev, and V. Murray, Traditional remedies and food supplements: a 5 year toxocological study (1991-95), Drug Saf, vol.17, issue.5, pp.342-56, 1997.

M. Unger and A. Frank, Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction, Rapid Commun Mass Spectrom RCM, vol.18, issue.19, pp.2273-81, 2004.

C. R. Sirtori, Aescin: pharmacology, pharmacokinetics and therapeutic profile, Pharmacol Res. sept, vol.44, issue.3, pp.183-93, 2001.

M. H. Pittler and E. Ernst, Horse chestnut seed extract for chronic venous insufficiency, Cochrane Database Syst Rev. 25 janv, issue.1, p.3230, 2006.

, European Medicines Agency. COMMUNITY HERBAL MONOGRAPH ON AESCULUS HIPPOCASTANUM L., SEMEN. 16 juill, vol.6, 2009.

U. Siebert, M. Brach, G. Sroczynski, and K. Berla, Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies, Int Angiol J Int Union Angiol. déc, vol.21, issue.4, pp.305-320, 2002.

D. Smet, P. A. Van-den-eertwegh, A. J. Lesterhuis, W. Stricker, and B. H. , Hepatotoxicity associated with herbal tablets, BMJ. 13 juill, vol.313, issue.7049, p.92, 1996.

R. F. Chandler, Herbal medicine: horse chestnut, Can. Pharm. J, vol.126, issue.297, pp.300-306, 1993.

A. Snow, D. Halpenny, G. Mcneill, and W. C. Torreggiani, Life-threatening rupture of a renal angiomyolipoma in a patient taking over-the-counter horse chestnut seed extract, J Emerg Med. déc, vol.43, issue.6, pp.401-403, 2012.

B. H. Hellum and O. G. Nilsen, In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products, Basic Clin Pharmacol Toxicol. mai, vol.102, issue.5, pp.466-75, 2008.

G. I. Bioactive and . Horse, The structures, inhibitory effects on ethanol absorption, and hypoglycemic activity of escins Ia, Ib, IIa, IIb, and IIIa from the seeds of Aesculus hippocastanum L

M. Steiner and H. G. Hillemanns, Venostasin retard in the management of venous problems during pregnancy, Phlebology, vol.5, pp.41-45, 1990.

A. Szegedi, R. Kohnen, A. Dienel, and M. Kieser, wort): randomised controlled double blind noninferiority trial versus paroxetine, BMJ. 5 mars, vol.330, issue.7490, p.503, 2005.

M. Fava, J. Alpert, A. A. Nierenberg, D. Mischoulon, M. W. Otto et al., A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder, J Clin Psychopharmacol, vol.25, issue.5, pp.441-448, 2005.

, Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study

, HERBA (WELL-ESTABLISHED MEDICINAL USE), European Medicines Agency. COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L, vol.7, 2009.

V. Parker, A. H. Wong, H. S. Boon, and M. V. Seeman, Adverse reactions to St John's Wort, Can J Psychiatry Rev Can Psychiatr. févr, vol.46, issue.1, pp.77-86, 2001.

A. J. Dean, G. M. Moses, and J. M. Vernon, Suspected withdrawal syndrome after cessation of St. John's wort, Ann Pharmacother. janv, vol.37, issue.1, p.150, 2003.

M. M. Lane-brown, Photosensitivity associated with herbal preparations of St John's wort (Hypericum perforatum), Med J Aust. 20 mars, vol.172, issue.6, p.302, 2000.

C. M. Schempp, B. Winghofer, R. Lüdtke, B. Simon-haarhaus, E. Schöpf et al., Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells, Br J Dermatol. mai, vol.142, issue.5, pp.979-84, 2000.

C. M. Schempp, B. Winghofer, K. Müller, J. Schulte-mönting, M. Mannel et al., Wort) on skin erythema and pigmentation induced by UVB, UVA, visible light and solar simulated radiation, Phytother Res. févr, vol.17, issue.2, pp.141-147, 2003.

S. Patel, R. Robinson, and M. Burk, Hypertensive crisis associated with St. John's Wort, Am J Med. 15 avr, vol.112, issue.6, pp.507-515, 2002.

, St John's wort-induced sexual dysfunction

D. Sur,

S. Irefin and J. Sprung, A possible cause of cardiovascular collapse during anesthesia: long-term use of St. John's Wort, J Clin Anesth. sept, vol.12, issue.6, pp.498-507, 2000.

K. Shimizu, M. Nakamura, K. Isse, and P. J. Nathan, First-episode psychosis after taking an extract of Hypericum perforatum, Hum Psychopharmacol. juin, vol.19, issue.4, pp.275-281, 2004.

R. D. Laird and M. Webb, Psychotic episode during use of St. John's wort, J Herbal Pharmacother, vol.1, pp.81-88, 2001.

C. Stevinson and E. E. St, John's wort trigger psychoses?, Int J Clin Pharmacol Ther. sept, vol.42, issue.9, pp.473-80, 2004.

M. Mannel, Drug interactions with St John's wort : mechanisms and clinical implications, Drug Saf, vol.27, issue.11, pp.773-97, 2004.

, Interactions médicamenteuses -ANSM : Agence nationale de sécurité du médicament et des produits de santé, ANSM. Thesaurus des interactions médicamenteuses -Mars, 2018.

J. Dugoua, E. Mills, P. D. Koren, and G. , John's wort (hypericum) during pregnancy and lactation, Can J Clin Pharmacol J Can Pharmacol Clin, vol.13, issue.3, pp.268-276, 2006.

A. Lee, R. Minhas, N. Matsuda, M. Lam, and S. Ito, The safety of St. John's wort (Hypericum perforatum) during breastfeeding, J Clin Psychiatry. août, vol.64, issue.8, pp.966-974, 2003.

A. Ngan and R. Conduit, A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passionflower) herbal tea on subjective sleep quality, Phytother Res. août, vol.25, issue.8, pp.1153-1162, 2011.

A. Movafegh, R. Alizadeh, F. Hajimohamadi, F. Esfehani, and M. Nejatfar, Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study, Anesth Analg. juin, vol.106, issue.6, pp.1728-1760, 2008.

P. Aslanargun, O. Cuvas, B. Dikmen, E. Aslan, and M. U. Yuksel, Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia, J Anesth. févr, vol.26, issue.1, pp.39-44, 2012.

, European Medicines Agency. Passiflora incarnata L., herba, 2016.

A. A. Fisher, P. Purcell, L. Couteur, and D. G. , Toxicity of Passiflora incarnata L, J Toxicol Clin Toxicol, vol.38, issue.1, pp.63-69, 2000.

G. W. Smith, T. M. Chalmers, and G. Nuki, Vasculitis associated with herbal preparation containing Passiflora extract, Br J Rheumatol. janv, vol.32, issue.1, pp.87-95, 1993.

, European Medicines Agency. Community herbal monograph on Passiflora incarnata L., herba. 25 mars, vol.7, 2014.

A. Capasso and L. Sorrentino, Pharmacological studies on the sedative and hypnotic effect of Kava kava and Passiflora extracts combination, Phytomedicine Int J Phytother Phytopharm. janv, vol.12, issue.1-2, pp.39-45, 2005.

M. C. Carrasco, J. R. Vallejo, M. Pardo-de-santayana, D. Peral, M. A. Martín et al., Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam, Phytother Res. déc, vol.23, issue.12, pp.1795-1801, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00483246

J. E. Polifka and J. M. Friedman, Medical genetics: 1. Clinical teratology in the age of genomics, CMAJ Can Med Assoc J. 6 août, vol.167, issue.3, pp.265-73, 2002.

. European-medicines-agency, . Community, . Senna-l, and F. Vahl, , vol.9, 2006.

. European-medicines-agency, . Community, . Monograph, . Cassia-senna-l, . Cassia et al., , vol.9, 2006.

, Anthranoid laxative abuse--a risk for colorectal cancer? -PubMed -NCBI [Internet]. [cité 30 sept, 2019.

G. A. Kune, Laxative use not a risk for colorectal cancer: data from the Melbourne Colorectal Cancer Study, Z Gastroenterol. févr, vol.31, issue.2, pp.140-143, 1993.

T. M. Rains, S. Agarwal, and K. C. Maki, Antiobesity effects of green tea catechins: a mechanistic review, J Nutr Biochem. janv, vol.22, issue.1, pp.1-7, 2011.

A. European-medicines, Community herbal monograph on Camellia sinensis (L.) Kuntze, non fermentatum folium, vol.5, 2013.

P. Nawrot, S. Jordan, J. Eastwood, J. Rotstein, A. Hugenholtz et al., Effects of caffeine on human health, Food Addit Contam. janv, vol.20, issue.1, pp.1-30, 2003.

G. Mazzanti, F. Menniti-ippolito, P. A. Moro, F. Cassetti, R. Raschetti et al., Hepatotoxicity from green tea: a review of the literature and two unpublished cases, Eur J Clin Pharmacol. avr, vol.65, issue.4, pp.331-372, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00534939

G. D. Liatsos, A. Moulakakis, I. Ketikoglou, and S. Klonari, Possible green tea-induced thrombotic thrombocytopenic purpura, Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 1 avr, vol.67, issue.7, pp.531-535, 2010.

, Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate

E. B. Golden, P. Y. Lam, A. Kardosh, K. J. Gaffney, E. Cadenas et al., Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors, vol.113, pp.5927-5964, 2009.

S. Samman, B. Sandstrom, B. Toft, M. Bukhave, K. Jensen et al., Green tea or rosemary extract added to foods reduces nonheme-iron absorption, Am J Clin Nutr, vol.73, pp.607-619, 2001.

, Probable antagonism of warfarin by green tea. -PubMed -NCBI [Internet]. [cité 30 sept, 2019.

, Valerian for sleep: a systematic review and meta-analysis

, Plainte d'insomnie : une place pour la phytothérapie traditionnelle. La revue Prescrire, vol.27, pp.564-571, 2007.

D. Benke, A. Barberis, S. Kopp, K. Altmann, M. Schubiger et al., GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts, Neuropharmacology. janv, vol.56, issue.1, pp.174-81, 2009.

, Valeriana officinalis L., radix, 2016.

A. European-medicines, European Union herbal monograph on Valeriana officinalis L., radix. 2 févr, vol.9, 2016.

D. M. Taibi, C. A. Landis, H. Petry, and M. V. Vitiello, A systematic review of valerian as a sleep aid: safe but not effective, Sleep Med Rev. juin, vol.11, issue.3, pp.209-239, 2007.

H. Bagheri, P. Broue, I. Lacroix, D. Larrey, J. P. Olives et al., Fulminant hepatic failure after herbal medicine ingestion in children, Therapie, vol.53, issue.1, pp.82-85, 1998.

, A case of valerian-associated hepatotoxicity

D. Sur,

T. Vassiliadis, P. Anagnostis, K. Patsiaoura, O. Giouleme, P. Katsinelos et al., Valeriana hepatotoxicity, Sleep Med. sept, vol.10, issue.8, p.935, 2009.

R. Bos, H. Hendriks, J. J. Scheffer, and H. J. Woerdenbag, Cytotoxic potential of valerian constituents and valerian tinctures, Phytomedicine Int J Phytother Phytopharm. mai, vol.5, issue.3, pp.219-244, 1998.

H. Hendriks, R. Bos, H. J. Woerdenbag, and A. S. Koster, Central nervous depressant activity of valerenic acid in the mouse, Planta Med. févr, vol.51, issue.1, pp.28-31, 1985.

J. P. Lambert, Des interactions médicamenteuses «naturelles, Le Médecin du Québec, vol.36, issue.9, pp.57-63, 2001.

, A developmental toxicity-screening test of valerian. -PubMed -NCBI [Internet]. [cité 30 sept, 2019.

, Effects of valerian consumption during pregnancy on cortical volume and the levels of zinc and copper in the brain tissue of mouse fetus

D. Sur,